PALO ALTO, Calif., Feb. 16, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has booked an order to equip a new two-room proton therapy center at the PTC St. Petersburg Center of Nuclear Medicine of the International Institute of Biological Systems in Russia. The equipment order was placed by Owen Kane Oncology Equipment, Inc. in New York which is supplying the system to the center in St. Petersburg.
Under the purchase agreement Varian will equip the new center with a ProBeam™ system as well as its ARIA information management and Eclipse treatment planning software products. The equipment order is valued at about $50 million not including service. Equipment delivery and installation is expected to commence in 2014 and patient treatments are scheduled to begin in 2016.
"We're very pleased to be able to bring Varian's cutting edge, clinically advanced and reliable technology to patients," said Dr. Arkadi Stolpner, President of the International Institute of Biological Systems Diagnostic and Treatment Center. "Our aim in purchasing the Varian ProBeam system is to help us meet our mission of saving lives."
"We are honored to be a part of a very important project that will help to make the most advanced proton therapy available to the people of Russia," said Tim Guertin, President and CEO of Varian Medical Systems. "The ProBeam system combines Varian's unmatched technology for intensity modulated proton therapy with advanced imaging, treatment planning, and information management capabilities that have been developed on the basis of decades of experience in clinical support. This is another exciting step forward for proton therapy."
"We selected Varian to supply our Proton Beam technology because we have confidence in their ability to deliver a quality product on a timely basis," said Philip Jacobus, President of Owen Kane Oncology Equipment. "We operate a Varian TrueBeam™ linear accelerator and Varian has proven to us that meeting the needs of the customer as well as the patient is a priority to them."
Proton therapy makes it possible to treat certain types of cancer more precisely and with potentially fewer side effects than with conventional radiation therapy. With proton therapy, the risk of damage to healthy tissues is reduced. The method can be applied for many of the most common types of cancer and offers advantages when treating tumors close to radiosensitive tissues. In pediatric patients the risk of developing a new, radiation-induced cancer later in life can be reduced.
Varian is currently installing and commissioning its ProBeam system at the Scripps Proton Center near San Diego. The company announced in January that it has booked an order to equip the Saudi Particle Therapy Center at the King Fahd Medical Center in Riyadh, Saudi Arabia. Varian also has been selected to provide equipment for new proton therapy centers at the University of Maryland and in Mestre, Italy. It has been identified as the preferred provider for a new center at Emory University near Atlanta.
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future business, including orders, revenues, backlog, or earnings growth; market acceptance of or transition to new products or technology for proton therapy, and any statements using the terms "can," "will," "scheduled," "expected," "goal," "mission," "possible," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase margins; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
FOR INFORMATION CONTACT:
Spencer Sias (650) 424-5782
SOURCE Varian Medical Systems